Free cash flow was positive only in 2025Q4 ($1.4M) and 2026Q3 ($7.7M) against FCF margins swinging from -56.7% to 9.1%, which suggests cash generation remains episodic and largely driven by working capital timing, such as the -$33.9M outflow in 2025Q3.
Adaptive Biotechnologies Corporation (ADPT) cash flow statement — 9-year operating, investing & financing cash flows
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 |
|---|
| Cash from Operations | -4.28M | -45.99M | -95.21M | -156.32M | -183.94M | -192.73M | -149.68M | 205.4M | -32.26M | -34.86M |
| Operating CF Margin % | - | -16.6% | -53.2% | -91.81% | -99.26% | -124.87% | -152.14% | 241.45% | -57.95% | -90.66% |
| Operating CF Growth % | 466.25% | 51.7% | 39.09% | 15.02% | 4.56% | -28.76% | -172.87% | 736.73% | 7.46% | - |
| Net Income | -70.52M | -59.5M | -159.59M | -225.25M | -200.19M | -207.28M | -146.23M | -68.61M | -46.45M | -42.83M |
| Depreciation & Amortization | 15.33M | 17.83M | 19.26M | 22.23M | 20.92M | 13.95M | 8.47M | 7.79M | 6M | 5.8M |
| Stock-Based Compensation | 46.15M | 51.48M | 53.61M | 0 | 0 | 0 | 24.76M | 13.12M | 11.15M | 7.01M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 773K | -1.88M | -1.24M | 637K |
| Other Non-Cash Items | 20.72M | 1.96M | 8.97M | 92.88M | 66.87M | 57.41M | 3.34M | 43K | 5K | 6K |
| Working Capital Changes | -15.76M | -57.77M | -17.45M | -46.18M | -71.55M | -56.82M | -40.8M | 254.93M | -1.72M | -5.47M |
| Change in Receivables | -21.85M | -8.65M | -3.74M | 2.03M | -22.65M | -7.36M | 2.61M | -7.82M | 775K | -2.43M |
| Change in Inventory | -275K | -998K | 1.94M | -2.84M | 817K | -5.2M | -4.99M | -1.23M | -3.05M | -2.7M |
| Change in Payables | -1.28M | 665K | 671K | -5.41M | 7.11M | 3.94M | 5.25M | -2.43M | 1.87M | -1.84M |
| Cash from Investing | -167.65M | 37.95M | 77.79M | 129.65M | 2.9M | 181.21M | -117.04M | -481.7M | 736K | 36.43M |
| Capital Expenditures | -4.54M | -2.96M | -3.66M | -10.7M | -16.35M | -61.75M | -18.8M | -11.2M | -6.32M | -2.51M |
| CapEx % of Revenue | 1.53% | 1.07% | 2.05% | 6.28% | 8.82% | 40.01% | 19.11% | 13.17% | 11.35% | 6.52% |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 98.24M | 470.5M | 19K | 85K |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | -98.24M | -470.5M | 19K | 122K |
| Cash from Financing | 192.52M | 30.4M | 241K | 2.25M | 132.26M | 27.15M | 293.59M | 319.92M | 1.25M | 50.03M |
| Debt Issued (Net) | 160.22M | 0 | 0 | 0 | 124.38M | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 18.39M | 30.4M | 241K | 2.25M | 7.89M | 26.72M | 272.16M | 320.85M | 0 | 49.83M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | -25M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 13.91M | 0 | 0 | 0 | 0 | 429K | 21.43M | -934K | 1.25M | 207K |
| Net Change in Cash | 20.6M | 22.37M | -17.18M | -24.97M | -49.03M | 15.63M | 26.86M | 43.62M | -30.27M | 51.61M |
| Free Cash Flow | -8.82M | -48.95M | -98.88M | -167.02M | -200.29M | -254.47M | -168.49M | 194.2M | -38.58M | -37.36M |
| FCF Margin % | -2.96% | -17.67% | -55.25% | -98.09% | -108.09% | -164.87% | -171.26% | 228.28% | -69.3% | -97.18% |
| FCF Growth % | 85.98% | 50.5% | 40.8% | 16.61% | 21.29% | -51.04% | -186.76% | 603.42% | -3.25% | - |
| FCF per Share | -0.05 | -0.32 | -0.67 | -1.16 | -1.41 | -1.81 | -1.28 | 1.56 | -0.37 | -0.35 |
| FCF Conversion (FCF/Net Income) | 0.13x | 0.77x | 0.60x | 0.69x | 0.92x | 0.93x | 1.02x | -2.99x | 0.69x | 0.81x |
| Interest Paid | -3.58M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying ADPT stock.
Adaptive Biotechnologies Corporation (ADPT) generated $-46.0M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
Adaptive Biotechnologies Corporation (ADPT) reported negative free cash flow of $48.9M in 2025, indicating capital requirements exceeded cash from operations.
Adaptive Biotechnologies Corporation (ADPT) spent $3.0M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.
Key Metrics
Top Statement Risk
Cash burn and liquidity runway
Metrics are mathematically derived from official filings.
Net Income Swings Diverge From Operating Cash
Based on reported quarterly figures, ADPT's operating cash flow has been consistently less negative than net income across most of the ten quarters, with OCF/NI ratios ranging widely from 0.16 to 3.34, signaling that reported losses are substantially driven by non-cash charges and timing effects rather than pure cash consumption.
The gap between net income and operating cash flow is the central signal in this dataset, and it is not stable enough to be read as a clean earnings-quality measure. The 2026Q3 ratio of 3.34 reflects a $2.9M net income alongside $9.6M of operating cash flow, which suggests working capital and non-cash add-backs such as the $10.4M SBC charge are doing much of the work. Investors should monitor whether this positive divergence persists or reverses once the working capital swing of -$8.0M normalizes.
Free Cash Flow Remains Negative Despite Revenue Growth
According to the reported quarterly figures, ADPT's free cash flow turned positive only in 2025Q4 at $1.4M and in 2026Q3 at $7.7M, with FCF margins swinging from -56.7% to 9.1%, indicating that cash generation remains episodic rather than structural.
The FCF trajectory shows that the business has not yet established consistent cash self-sufficiency, even as the top line expands. Two positive quarters within the last five suggest an inflection is possible but unconfirmed, and the 2026Q2 and 2026Q1 burns of -$7.6M and -$10.3M indicate the prior trend has not fully reversed. Analysts should treat the recent positive FCF as a potential turning point requiring confirmation over additional periods.
Working Capital Volatility Drives Cash Timing
Based on reported figures, working capital changes have ranged from a -$33.9M outflow in 2025Q3 to a $3.1M inflow in 2024Q4, and this volatility appears to account for a large share of the quarter-to-quarter divergence between operating cash flow and earnings.
The magnitude of the 2025Q3 working capital outflow suggests significant receivable build or payables timing, which may have depressed operating cash flow despite a positive $9.5M net income that quarter. Such lumpiness is consistent with milestone-driven and project-based revenue recognition, which can shift collections across periods. Investors should monitor whether the 2026Q3 inflow of positive operating cash reflects genuine collection improvement or a temporary timing benefit.
Minimal Capital Deployment Amid Cash Preservation
As reported in the cash flow statements, ADPT paid no dividends in any period, and buybacks appear only in 2026Q2 at $25.0M, suggesting the company has prioritized liquidity over shareholder returns during this window.
The absence of dividends is unsurprising for a company with persistent negative FCF, but the $25.0M buyback in 2026Q2 is notable given the concurrent negative operating cash flow of -$6.4M and net loss of -$39.8M. This may indicate opportunistic repurchasing or an offset against dilution, and the source of funds warrants further investigation. Such an allocation appears difficult to reconcile with a capital-preservation posture and should be weighed against the company's reported cash position.
Positive Quarters May Not Signal Durable Improvement
Based on reported figures, ADPT's two recent positive FCF quarters rest on a single $9.5M net income period and a $33.9M working capital swing, suggesting that the apparent inflection may reflect timing rather than sustained operating improvement.
Treating the 2026Q3 FCF of $7.7M as evidence of a durable turn overlooks that trailing cumulative free cash flow across the ten quarters remains deeply negative. The SBC add-back of $10.4M contributes materially to operating cash flow, and a substantial portion of reported cash generation may reflect non-cash compensation rather than economic cash earnings. Investors should monitor whether FCF stays positive once working capital normalizes and SBC is treated as a real economic cost.